Lot-to-Lot Consistency, Safety, Tolerability, and Immunogenicity of an Investigational Hexavalent Vaccine in US Infants

Stanley L. Block, Nicola P. Klein, Kwabena Sarpong, Stephen Russell, John Fling, Maria Petrecz, Sheryl Flores, Jin Xu, Guanghan Liu, Jon E. Stek, Ginamarie Foglia, Andrew W. Lee

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

BACKGROUND: This multicenter Phase III study (NCT01340937) evaluated the consistency of immune responses to 3 separate lots of DTaP5-IPV-Hib-HepB, an investigational hexavalent vaccine (HV). METHODS: Healthy infants were randomized (2:2:2:1) to receive HV or Pentacel (Control). Groups 1, 2, and 3 received HV at 2, 4, and 6 months, and Control at 15 months. Group 4 received Control at 2, 4, 6, and 15 months, plus Recombivax HB (HepB) at 2 and 6 months. Concomitant Prevnar 13 (PCV13) was given to all groups at 2, 4, 6, and 15 months; pentavalent rotavirus vaccine (RV5) was given to all groups at 2, 4, and 6 months.Blood specimens (3mL-to-5mL) were collected immediately prior to administration of Dose 1, Postdose 3, immediately before toddler dose, and after toddler dose. Adverse events were recorded after each vaccination. RESULTS: The 3 manufacturing lots of HV induced consistent antibody responses to all antigens. Immunogenicity of HV was non-inferior to control for all antibodies, except for pertussis filamentous hemagglutinin (FHA) geometric mean concentration (GMC) postdose 3, and pertussis pertactin (PRN) GMC after toddler dose. Postdose 3 immunogenicity of concomitantly administered PCV13 was generally similar (except for serotype 6B) when given with HV or control.Adverse events of HV were similar to control, except for a higher rate of fever ≥ 38.0°C (49.2% vs. 35.4%, estimated difference 13.7 % [8.4, 18.8]). CONCLUSION: HV demonstrated lot-to-lot manufacturing consistency; safety and immunogenicity were comparable with the licensed vaccines. HV provides a new combination vaccine option within the US 2,4,6 month vaccine series.

Original languageEnglish (US)
JournalPediatric Infectious Disease Journal
DOIs
StateAccepted/In press - Nov 11 2016

Fingerprint

Vaccines
Safety
Whooping Cough
Combined Vaccines
Haemophilus influenzae type b
Hemagglutinins
Antibody Formation
Vaccination
Fever
Antigens
Antibodies

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Lot-to-Lot Consistency, Safety, Tolerability, and Immunogenicity of an Investigational Hexavalent Vaccine in US Infants. / Block, Stanley L.; Klein, Nicola P.; Sarpong, Kwabena; Russell, Stephen; Fling, John; Petrecz, Maria; Flores, Sheryl; Xu, Jin; Liu, Guanghan; Stek, Jon E.; Foglia, Ginamarie; Lee, Andrew W.

In: Pediatric Infectious Disease Journal, 11.11.2016.

Research output: Contribution to journalArticle

Block, SL, Klein, NP, Sarpong, K, Russell, S, Fling, J, Petrecz, M, Flores, S, Xu, J, Liu, G, Stek, JE, Foglia, G & Lee, AW 2016, 'Lot-to-Lot Consistency, Safety, Tolerability, and Immunogenicity of an Investigational Hexavalent Vaccine in US Infants', Pediatric Infectious Disease Journal. https://doi.org/10.1097/INF.0000000000001405
Block, Stanley L. ; Klein, Nicola P. ; Sarpong, Kwabena ; Russell, Stephen ; Fling, John ; Petrecz, Maria ; Flores, Sheryl ; Xu, Jin ; Liu, Guanghan ; Stek, Jon E. ; Foglia, Ginamarie ; Lee, Andrew W. / Lot-to-Lot Consistency, Safety, Tolerability, and Immunogenicity of an Investigational Hexavalent Vaccine in US Infants. In: Pediatric Infectious Disease Journal. 2016.
@article{2c4f7c4c5b8b46ecae45cef1bc100846,
title = "Lot-to-Lot Consistency, Safety, Tolerability, and Immunogenicity of an Investigational Hexavalent Vaccine in US Infants",
abstract = "BACKGROUND: This multicenter Phase III study (NCT01340937) evaluated the consistency of immune responses to 3 separate lots of DTaP5-IPV-Hib-HepB, an investigational hexavalent vaccine (HV). METHODS: Healthy infants were randomized (2:2:2:1) to receive HV or Pentacel (Control). Groups 1, 2, and 3 received HV at 2, 4, and 6 months, and Control at 15 months. Group 4 received Control at 2, 4, 6, and 15 months, plus Recombivax HB (HepB) at 2 and 6 months. Concomitant Prevnar 13 (PCV13) was given to all groups at 2, 4, 6, and 15 months; pentavalent rotavirus vaccine (RV5) was given to all groups at 2, 4, and 6 months.Blood specimens (3mL-to-5mL) were collected immediately prior to administration of Dose 1, Postdose 3, immediately before toddler dose, and after toddler dose. Adverse events were recorded after each vaccination. RESULTS: The 3 manufacturing lots of HV induced consistent antibody responses to all antigens. Immunogenicity of HV was non-inferior to control for all antibodies, except for pertussis filamentous hemagglutinin (FHA) geometric mean concentration (GMC) postdose 3, and pertussis pertactin (PRN) GMC after toddler dose. Postdose 3 immunogenicity of concomitantly administered PCV13 was generally similar (except for serotype 6B) when given with HV or control.Adverse events of HV were similar to control, except for a higher rate of fever ≥ 38.0°C (49.2{\%} vs. 35.4{\%}, estimated difference 13.7 {\%} [8.4, 18.8]). CONCLUSION: HV demonstrated lot-to-lot manufacturing consistency; safety and immunogenicity were comparable with the licensed vaccines. HV provides a new combination vaccine option within the US 2,4,6 month vaccine series.",
author = "Block, {Stanley L.} and Klein, {Nicola P.} and Kwabena Sarpong and Stephen Russell and John Fling and Maria Petrecz and Sheryl Flores and Jin Xu and Guanghan Liu and Stek, {Jon E.} and Ginamarie Foglia and Lee, {Andrew W.}",
year = "2016",
month = "11",
day = "11",
doi = "10.1097/INF.0000000000001405",
language = "English (US)",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Lot-to-Lot Consistency, Safety, Tolerability, and Immunogenicity of an Investigational Hexavalent Vaccine in US Infants

AU - Block, Stanley L.

AU - Klein, Nicola P.

AU - Sarpong, Kwabena

AU - Russell, Stephen

AU - Fling, John

AU - Petrecz, Maria

AU - Flores, Sheryl

AU - Xu, Jin

AU - Liu, Guanghan

AU - Stek, Jon E.

AU - Foglia, Ginamarie

AU - Lee, Andrew W.

PY - 2016/11/11

Y1 - 2016/11/11

N2 - BACKGROUND: This multicenter Phase III study (NCT01340937) evaluated the consistency of immune responses to 3 separate lots of DTaP5-IPV-Hib-HepB, an investigational hexavalent vaccine (HV). METHODS: Healthy infants were randomized (2:2:2:1) to receive HV or Pentacel (Control). Groups 1, 2, and 3 received HV at 2, 4, and 6 months, and Control at 15 months. Group 4 received Control at 2, 4, 6, and 15 months, plus Recombivax HB (HepB) at 2 and 6 months. Concomitant Prevnar 13 (PCV13) was given to all groups at 2, 4, 6, and 15 months; pentavalent rotavirus vaccine (RV5) was given to all groups at 2, 4, and 6 months.Blood specimens (3mL-to-5mL) were collected immediately prior to administration of Dose 1, Postdose 3, immediately before toddler dose, and after toddler dose. Adverse events were recorded after each vaccination. RESULTS: The 3 manufacturing lots of HV induced consistent antibody responses to all antigens. Immunogenicity of HV was non-inferior to control for all antibodies, except for pertussis filamentous hemagglutinin (FHA) geometric mean concentration (GMC) postdose 3, and pertussis pertactin (PRN) GMC after toddler dose. Postdose 3 immunogenicity of concomitantly administered PCV13 was generally similar (except for serotype 6B) when given with HV or control.Adverse events of HV were similar to control, except for a higher rate of fever ≥ 38.0°C (49.2% vs. 35.4%, estimated difference 13.7 % [8.4, 18.8]). CONCLUSION: HV demonstrated lot-to-lot manufacturing consistency; safety and immunogenicity were comparable with the licensed vaccines. HV provides a new combination vaccine option within the US 2,4,6 month vaccine series.

AB - BACKGROUND: This multicenter Phase III study (NCT01340937) evaluated the consistency of immune responses to 3 separate lots of DTaP5-IPV-Hib-HepB, an investigational hexavalent vaccine (HV). METHODS: Healthy infants were randomized (2:2:2:1) to receive HV or Pentacel (Control). Groups 1, 2, and 3 received HV at 2, 4, and 6 months, and Control at 15 months. Group 4 received Control at 2, 4, 6, and 15 months, plus Recombivax HB (HepB) at 2 and 6 months. Concomitant Prevnar 13 (PCV13) was given to all groups at 2, 4, 6, and 15 months; pentavalent rotavirus vaccine (RV5) was given to all groups at 2, 4, and 6 months.Blood specimens (3mL-to-5mL) were collected immediately prior to administration of Dose 1, Postdose 3, immediately before toddler dose, and after toddler dose. Adverse events were recorded after each vaccination. RESULTS: The 3 manufacturing lots of HV induced consistent antibody responses to all antigens. Immunogenicity of HV was non-inferior to control for all antibodies, except for pertussis filamentous hemagglutinin (FHA) geometric mean concentration (GMC) postdose 3, and pertussis pertactin (PRN) GMC after toddler dose. Postdose 3 immunogenicity of concomitantly administered PCV13 was generally similar (except for serotype 6B) when given with HV or control.Adverse events of HV were similar to control, except for a higher rate of fever ≥ 38.0°C (49.2% vs. 35.4%, estimated difference 13.7 % [8.4, 18.8]). CONCLUSION: HV demonstrated lot-to-lot manufacturing consistency; safety and immunogenicity were comparable with the licensed vaccines. HV provides a new combination vaccine option within the US 2,4,6 month vaccine series.

UR - http://www.scopus.com/inward/record.url?scp=84995538613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995538613&partnerID=8YFLogxK

U2 - 10.1097/INF.0000000000001405

DO - 10.1097/INF.0000000000001405

M3 - Article

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

ER -